Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MESO 
Mesoblast Ltd (MESO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: MESO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $27
1 Year Target Price $27
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 480.22% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.90B USD | Price to earnings Ratio - | 1Y Target Price 27 |
Price to earnings Ratio - | 1Y Target Price 27 | ||
Volume (30-day avg) 3 | Beta 1.17 | 52 Weeks Range 6.00 - 22.00 | Updated Date 09/14/2025 |
52 Weeks Range 6.00 - 22.00 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-08-28 | When - | Estimate -0.4 | Actual -0.04 |
Profitability
Profit Margin - | Operating Margin (TTM) -302.37% |
Management Effectiveness
Return on Assets (TTM) -5.37% | Return on Equity (TTM) -18.95% |
Valuation
Trailing PE - | Forward PE 454.55 | Enterprise Value 1854367645 | Price to Sales(TTM) 110.4 |
Enterprise Value 1854367645 | Price to Sales(TTM) 110.4 | ||
Enterprise Value to Revenue 107.82 | Enterprise Value to EBITDA -6.55 | Shares Outstanding 128117000 | Shares Floating 774830326 |
Shares Outstanding 128117000 | Shares Floating 774830326 | ||
Percent Insiders 0.09 | Percent Institutions 2.68 |
Upturn AI SWOT
Mesoblast Ltd
Company Overview
History and Background
Mesoblast Ltd was founded in 2004 and is an Australian biotechnology company focused on developing allogeneic cellular medicines. It has focused on developing therapies for inflammatory diseases.
Core Business Areas
- Regenerative Medicine: Development and commercialization of allogeneic cellular medicines for inflammatory conditions.
Leadership and Structure
The key leaders of Mesoblast include the CEO and a board of directors. The organizational structure is typical for a biotechnology company, involving research, development, clinical trials, and commercial functions.
Top Products and Market Share
Key Offerings
- Remestemcel-L (RYONCIL): Cellular therapy for acute graft versus host disease (aGVHD). Market share is limited due to regulatory hurdles and challenges in gaining widespread adoption. Competitors include traditional immunosuppressants.
- MPC-150-IM: Cellular therapy for chronic heart failure. It is in clinical trials.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, with advancements in cell therapies and gene therapies. It is driven by unmet medical needs and technological advancements.
Positioning
Mesoblast aims to be a leader in allogeneic cellular medicines, with a focus on inflammatory diseases. Competitive advantage is its proprietary technology platform.
Total Addressable Market (TAM)
The TAM for cell therapies is estimated to be in the tens of billions of USD. Mesoblast is positioned to capture a portion of this market, but faces challenges in obtaining regulatory approvals and commercializing its products.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Pipeline of cellular medicine candidates
- Established manufacturing capabilities
- Clinical trial data supporting efficacy
Weaknesses
- Regulatory hurdles and delays
- High costs of development and manufacturing
- Limited commercial success to date
- Financial performance concerns
Opportunities
- Expanding into new indications
- Partnering with larger pharmaceutical companies
- Receiving regulatory approvals for its products
- Growing demand for cell therapies
Threats
- Competition from other biotechnology companies
- Changes in regulatory landscape
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- CRSP
- BLUE
- BPMC
- NK
- AGEN
Competitive Landscape
Mesoblast has proprietary technology, but struggles to compete with larger firms. The company's advantages lie in its allogeneic cell therapy platform, while its disadvantages include the need for continuous funding and regulatory risks.
Growth Trajectory and Initiatives
Historical Growth: Limited revenue growth to date. Growth is dependent on regulatory approvals and commercialization.
Future Projections: Future growth is dependent on the success of its clinical trials and commercialization efforts. Analyst estimates vary widely.
Recent Initiatives: Focused on obtaining regulatory approvals for Remestemcel-L and advancing its pipeline.
Summary
Mesoblast is an Australian biotechnology company which has not yet demonstrated strong commercial viability due to revenue difficulties. The company needs regulatory approvals, cash flow, and competitive challenges to resolve. This company's main problem is regulatory approval, but its technology shows promise and may lead to success. Thus Mesoblast is in need of capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports, industry databases.
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesoblast Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2015-11-13 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.mesoblast.com |
Full time employees 81 | Website https://www.mesoblast.com | ||
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.